Blog
RSS FeedPosted by Michael Wonder on 27 Jan 2021
On the role of cost effectiveness thresholds in health care priority setting
25 January 2021 - In the past few years, empirical estimates of the marginal cost at which health care produces a ...
Posted by Michael Wonder on 04 Dec 2020
ICER opens nominations for new members of its voting panels
2 December 2020 - Independent panel members debate the evidence on the effectiveness and value of new drugs and other ...
Posted by Michael Wonder on 03 Dec 2020
The real worth of cancer drugs
1 December 2020 - In November, 2020, we witnessed one of the most awaited elections in recent times—the USA elected Joe ...
Posted by Michael Wonder on 29 Nov 2020
Will COVID-19 vaccines be cost effective—and does it matter?
26 November 2020 - The costs of other pandemic measures mean that covid-19 vaccines will probably turn out to be ...
Posted by Michael Wonder on 19 Nov 2020
Consideration of value-based pricing for treatments and vaccines is important, even in the COVID-19 pandemic
19 November 2020 - Prices send signals about consumer preferences and thus stimulate producers to make more of what people want. ...
Posted by Michael Wonder on 07 Nov 2020
A health opportunity cost threshold for cost effectiveness analysis in the United State
3 November 2020 - Cost effectiveness analysis is an important tool for informing treatment coverage and pricing decisions, yet no consensus ...
Posted by Michael Wonder on 23 Oct 2020
Efficiency ratio and rocketing drug prices: old concerns and new possibilities
23 October 2020 - One of the most significant phenomena in the recent years concerning the pharmaceutical industry and, at ...
Posted by Michael Wonder on 06 Oct 2020
FDA announces all time low rates for FY2021 priority review vouchers
5 October 2020 - The US FDA has announced historic low rates for the fiscal year 2021 fees to use ...
Posted by Michael Wonder on 05 Oct 2020
De-adopting low value care: evidence, eminence and economics
2 October 2020 - An often cited shortcoming of the US health care system is the slow pace with which ...
Posted by Michael Wonder on 12 Jul 2020
Does cost effectiveness analysis really need to abandon the incremental cost effectiveness ratio to embrace net benefit?
10 July 2020 - The central task of cost-effectiveness analysis is to identify strategies that maximise health within finite budgets. ...
Posted by Michael Wonder on 11 Jul 2020
How can cancer drug prices better match their benefits? Germany offers a cost-saving model
10 July 2020 - After Germany revamped its approach to purchasing medicines a decade ago, the prices negotiated by the ...
Posted by Michael Wonder on 23 Jun 2020
The case for using novel value elements when assessing COVID-19 vaccines and therapeutics
23 June 2020 - In the span of mere weeks, the novel coronavirus (COVID-19) has upended modern life. Schools and businesses ...
Posted by Michael Wonder on 20 Jun 2020
ICER to assess whether the most significant prescription drug price increases are supported by new clinical evidence
19 June 2020 - Public input on drugs of concern will be accepted through 17 July 2020. ...
Posted by Michael Wonder on 18 Jun 2020
Trump administration seeks to encourage ‘value-based’ drug pricing deals with new proposal
17 June 2020 - The Trump administration wants to revamp certain Medicaid rules about drug prices in hopes of encouraging ...
Posted by Michael Wonder on 15 Jun 2020
COVID-19 and remdesivir: rethinking how we measure a drug’s ‘value’
15 June 2020 - As pharmaceutical and biotech companies scramble to identify treatments for COVID-19, a new disease that initially ...